Cambridge Healthtech Institute’s 2nd Annual

Next-Generation Immunotherapies

Engineering Next-Gen Biotherapeutics in Immuno-Oncology

August 13-14, 2020



Cambridge Healthtech Institute's Second Annual Next-Generation Immunotherapies meeting will feature presentations on the latest immunotherapy technologies from emerging companies. Learn about engineering the next-generation immunotherapies coming down the pipeline, including bi-specific and multi-specific antibody constructs, innovative multivalent therapeutics, immunotherapeutic fusion proteins, cytokines, antibody-drug conjugates, small molecules, engineered cells, and other innovative approaches.

Preliminary Agenda

CYTOKINES AS EMERGING TARGETS AND BIOTHERAPEUTICS

Developing Immunocytokine Combination Strategies in Prostate Cancer

Ravi Madan, MD, Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute, NIH

CUE-102 Immuno-STATs for Selective Targeting and Expansion of WT1-Specific T Cells for the Treatment of HLA-A02 and/or HLA-A24 Cancer Patients Expressing WT1

Saso Cemerski, PhD, Senior Director, Immuno-Oncology and Translational Immunology, Cue Biopharma

NKTR-255: A Potent NK and CD8 Memory T Cell Mobilizer for Immunotherapy

Loui Madakamutil, PhD, Senior Vice President, Discovery Research, Nektar Therapeutics

Targeting Soluble TNF to Overcome Trastuzumab Resistance in HER2+ Breast Cancer

Raymond Tesi, MD, CEO/CMO, INmune Bio

TARGETING INNATE IMMUNITY

SBT6050, a HER2-Directed TLR8 ImmunoTAC™ Therapeutic, is a Potent Human Myeloid Cell Agonist with Tumor-Localized Activity

Valerie Odegard, PhD, CSO, Silverback Therapeutics

NEOANTIGEN SELECTION AND THERAPEUTIC TARGETING

Clinical Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes

Philip Arlen, MD, President & CEO, Precision Biologics

Talk Title to be Announced

Stephen Schoenberger, PhD, Co-Director, San Diego Center for Precision Immunotherapy; Professor, La Jolla Institute for Allergy and Immunology

Talk Title to be Announced

Karin Jooss, PhD, CSO, Gritstone Oncology

True Tumor-Rejection Mediating Neo-Epitopes – Embarrassment of Riches

Pramod Srivastava, MD, PhD, Director, Carole and Ray Neag Comprehensive Cancer Center; Professor, Immunology and Medicine, University of Connecticut School of Medicine



* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Korean